Magnevist and Joint lock - a phase IV clinical study of FDA data

Summary:

Joint lock is reported as a side effect among people who take Magnevist (gadopentetate dimeglumine), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Omniscan, and have Nuclear magnetic resonance imaging abdominal.

The phase IV clinical study analyzes which people have Joint lock when taking Magnevist. It is created by eHealthMe based on reports of 10,515 people who have side effects when taking Magnevist from the FDA, and is updated regularly.

What is Magnevist?

Magnevist has active ingredients of gadopentetate dimeglumine. eHealthMe is studying from 10,524 Magnevist users. Check the latest studies of Magnevist.

What is Joint lock?

Joint lock is found to be associated with 302 drugs and 490 conditions by eHealthMe. Check the latest studies of Joint lock.

On Jul, 08, 2026

10,515 people reported to have side effects when taking Magnevist.
Among them, 44 people (0.42%) have Joint lock.

Among these 44 people:

How long have people been on Magnevist when they have Joint lock? *

What is the gender of people who have Joint lock when taking Magnevist? *

female: 67.44 %
male: 32.56 %

What is the age of people who have Joint lock when taking Magnevist? *

What are other drugs people take besides Magnevist? *

Renagel: 26 people, 59.09%
Omniscan: 26 people, 59.09%
Optimark: 24 people, 54.55%
Multihance: 17 people, 38.64%
Prohance: 17 people, 38.64%
Prevacid: 16 people, 36.36%
Plavix: 15 people, 34.09%
Zoloft: 13 people, 29.55%
Gabitril: 13 people, 29.55%
Midodrine Hydrochloride: 13 people, 29.55%

What are other side effects people have besides Joint lock? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 42 people, 95.45%
Pain: 40 people, 90.91%
Oedema Peripheral (superficial swelling): 38 people, 86.36%
Skin Induration (an abnormally hard spot or area on the skin): 38 people, 86.36%
Joint Range Of Motion Decreased (disease of joint movement): 34 people, 77.27%
Skin Tightness: 31 people, 70.45%
Extremity Contracture (permanent shortening of a muscle or joint of arms and legs): 26 people, 59.09%
Skin Discoloration: 25 people, 56.82%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 24 people, 54.55%
Skin Hyperpigmentation (disorders affect the colour of your skin): 24 people, 54.55%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Abdominal: 9 people, 20.45%
Pain: 8 people, 18.18%
Joint Swelling: 7 people, 15.91%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 13.64%
Nuclear Magnetic Resonance Imaging Brain: 5 people, 11.36%
Joint Pain: 5 people, 11.36%
Tumor: 2 people, 4.55%
Thyroid Cancer: 2 people, 4.55%
Oedema Peripheral (superficial swelling): 2 people, 4.55%
Immunodeficiency Disorders: 2 people, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Magnevist and have Joint lock?

- Check whether Joint lock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Magnevist:

Magnevist (10,524 reports)

Joint lock treatments and more:

Joint lock (3,416 reports)

Browse all side effects of Magnevist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint lock:

Joint lock (302 drugs)

Browse all the conditions that are associated with Joint lock:

Joint lock (490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadopentetate dimeglumine (the active ingredients of Magnevist) and Magnevist (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.